T-Mobile & Sprint refute reports about $26Bn merger in jeopardy
By Nikita Chaurasia  Date: 2019-04-18

T-Mobile & Sprint refute reports about $26Bn merger in jeopardy

T-Mobile US Inc. and Sprint Corp reportedly claim that they have not received legal notice from the United States Justice Department that their $26 billion strategic deal could be rejected by federal regulators without major refinements. The companies in fact, are consistently working with government officials to accomplish the deal, stated sources familiar with the development.

Recent reports claim that the DOJ’s antitrust staff have notified company authorities that the department will most likely reject the deal considering it could eliminate competition in the wireless business space by slashing the number of key carriers. The DOJ staff had reportedly made the announcement over a private meeting in the presence of T-Mobile and Sprint representatives.

Regulators are anticipated to soon indicate their consent about the merger deal. In early April, the two sides began discussing the merger and what is being examined by the government. But then the DOJ’s staff didn’t conclude anything and provided no recommendations about making significant changes in the combined company for the transaction to advance, stated sources familiar with the matter.

The DOJ’s staff is reportedly concerned about the possibilities of anti-competitive behavior considering the decline in wireless carriers. Makan Delrahim, DOJ Antitrust Chief is recognized as a pro-business advocate, however, he will have to thoroughly examine the antitrust implications of the transaction, reported sources.

Apparently, the merger between the telecom giants is one of the carefully followed transactions on Wall Street and in Washington D.C. During Obama administration too the companies failed to get the deal approved by the Federal Communications Commission’s political regulatory apparatus and the DOJ’s antitrust division.

However, company officials state having a better chance of approval from the Trump administration’s DOJ and FCC. Officials also claimed that the loss of one major wireless carrier would hardly impact pricing for consumers as the merged entity will still witness tough competition from AT&T and Verizon.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...